While CELMoDs frequently cause neutropenia, this effect is most pronounced in early cycles and manageable with growth factors. This contrasts sharply with the persistent, quality-of-life-impairing non-hematologic side effects of lenalidomide, such as rash and severe fatigue. This trade-off results in a significantly better long-term tolerability profile for patients.

Previous neutropenic diet studies were flawed by using fever as an endpoint. Since only about 25% of fevers represent a true, documented infection, this trial's use of a robust "major infection" endpoint provided a much clearer and more accurate signal of dietary risk, revealing differences other studies missed.

With highly effective CLL therapies, primary causes of mortality are now infections and secondary cancers from immunodeficiency. Research is now focusing on immune reconstitution after treatment, marking a pivotal shift towards managing long-term survivorship challenges beyond just controlling the leukemia itself.

While these drugs can cause neutropenia, it rarely leads to infections. Patients often feel clinically well despite low neutrophil counts. This 'paper problem' can usually be managed with G-CSF without needing to dose-reduce the primary CLL therapy.

Three-year data for odronextumab, given until progression in follicular lymphoma, reveals a high rate of severe (Grade 3+) infections (45%), including fatal events. This highlights a critical safety concern with continuous dosing and strengthens the clinical argument for using fixed-duration bispecific regimens to mitigate long-term toxicity.

For patients with pre-cancerous conditions like MGUS and smoldering myeloma, diet can significantly influence their progression to an active myeloma diagnosis. This positions dietary intervention not just as supportive care but as a key tool for mitigating disease progression.

Erik van den Berg highlights a critical paradox in the current standard of care for BK virus infections post-transplant. The only available intervention is lowering immunosuppression to fight the virus, but this simultaneously increases the probability that the patient's immune system will reject the newly transplanted organ.

Contrary to expectations, a trial found that allowing fresh fruits and vegetables did not increase caloric intake, protein intake, or patient-reported quality of life compared to a strict neutropenic diet. Both diets resulted in suboptimal nutrition, eliminating the presumed key benefits of a less restrictive approach.

The increased infection rate in patients on a liberalized diet was specifically driven by a twofold increase in organisms originating from the GI tract. This provides a strong mechanistic link, suggesting the diet introduces pathogens that translocate through the gut barrier compromised by chemotherapy or transplant.